JAPANESE JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS最新文献

{"title":"Report of the 6th Annual Meeting of the Toukai & Hokuriku Region of the JSCPT","authors":"T. Yamauchi","doi":"10.3999/jscpt.53.6_269","DOIUrl":"https://doi.org/10.3999/jscpt.53.6_269","url":null,"abstract":"","PeriodicalId":14602,"journal":{"name":"JAPANESE JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45999975","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Report of the 6th Annual Meeting of the Kyushu & Okinawa Region of the JSCPT","authors":"M. Kuroiwa, F. Kaneko, A. Nishi","doi":"10.3999/jscpt.53.6_275","DOIUrl":"https://doi.org/10.3999/jscpt.53.6_275","url":null,"abstract":"","PeriodicalId":14602,"journal":{"name":"JAPANESE JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41547915","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of Regulations and Status of Promoting Drug Development and Authorization of Pediatric Indications among Japan, the United States and the United Kingdom","authors":"Mizuki Suwa, S. Miyake, H. Urushihara","doi":"10.3999/jscpt.53.6_225","DOIUrl":"https://doi.org/10.3999/jscpt.53.6_225","url":null,"abstract":"","PeriodicalId":14602,"journal":{"name":"JAPANESE JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43018044","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Public Awareness of Industrial Use of Research Data Generated from Provided Biological Samples： Consideration from the Results of the Questionnaire Survey","authors":"Ayako Kamisato, Kazuyo Arisawa","doi":"10.3999/jscpt.53.6_235","DOIUrl":"https://doi.org/10.3999/jscpt.53.6_235","url":null,"abstract":"","PeriodicalId":14602,"journal":{"name":"JAPANESE JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41670580","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Study Protocol for a Randomized Double-blind Placebo-controlled Phase 2 Clinical Trial to Assess Anti-inflammatory Effect of Colchicine (DRC3633) in Mild to Moderately Severe COVID‒19 Patients (DRC-06C)","authors":"T. Kinjo, Yumi Ikehara, T. Misumi, Kouji Yamamoto, K. Murotani, T. Ogura, Toshio Miyata, Shin‐ichiro Ueda","doi":"10.3999/jscpt.53.6_199","DOIUrl":"https://doi.org/10.3999/jscpt.53.6_199","url":null,"abstract":"Introduction: Given that coronavirus disease 2019(COVID-19)aggravation is associated with an excessive host immune response, complementary anti-inflammatory treatment is recommended in severe disease. Although dexamethasone is a widely used anti-inflammatory agent in COVID-19 patients with respiratory failure, its use in patients with mild COVID-19 not receiving oxygen could have harmful effects. Colchicine, an anti-inflammatory drug, blocks the upstream immune response by inhibiting NALP3 inflammasome activation. This study aimed to assess the efficacy and safety of low-dose colchicine(DRC 3633)in mild COVID-19. Method(s): This study is a prospective, multicenter, placebo-controlled, double-blind randomized, phase 2 clinical trial patients with moderate COVID-19 admitted at nine hospitals in Japan (jRCT2071200078). The primary endpoint is area under the curve(AUC)for the amount of change of serum hypersensitive C-reactive protein(hs-CRP)from baseline to 1, 2, and 4 weeks after initiating investigational drug. Study participants will be randomly assigned to the colchicine or placebo group at a 1:1 ratio. On day 1, patients in the colchicine group will receive 1 mg of colchicine, followed by 0.5 mg of colchicine after 2 h barring gastrointestinal complications. From day 2 to 28, 0.5 mg of colchicine will be administered once daily. Discussion(s): An appropriate anti-inflammatory strategy is critical to improve the outcome of severe COVID-19 patients. This study will assess the efficacy of low-dose colchicine not only by the AUC of the amount of change in serum hs-CRP from baseline to several time points, but also by evaluating whether the result of the primary endpoint is consistent with other relevant biomarkers and clinical parameters measured as secondary endpoints. Copyright © 2022 the Japanese Society of Clinical Pharmacology and Therapeutics (JSCPT)","PeriodicalId":14602,"journal":{"name":"JAPANESE JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46470781","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Novel Gene Therapies Technology for Spinal Cord Injury (SCI) Therapy: Efficient Direct Lineage Reprogramming","authors":"Chunggoo Kim, Hyun Soo Shim, Yujung Chang, Hyeonjoo Im, Junsang Yoo","doi":"10.33597/jcpt-03-id1028","DOIUrl":"https://doi.org/10.33597/jcpt-03-id1028","url":null,"abstract":"What is known and objectives: Spinal Cord Injury (SCI) is defined for the last few decades as patients getting wheelchair bound and under medication for a lifetime [1]. Medical battery for SCI is very limited which often results in heightened frustration for the caregivers who land up with no solid solution to the condition. However, in recent times due to the huge volume of research, neuroscience has progressed massively through GT offering better insight and high hopes of neural regeneration and functional rehabilitation [2]. As GT technology becomes more popular as an emerging therapeutic method, many studies using a manufactured virus (AAV, retro, adeno, lenti) are opening up promising research avenues [3-5]. In this review, we dealt with Direct Lineage Reprogramming (DLR) technology for a novel GT method for SCI patients.","PeriodicalId":14602,"journal":{"name":"JAPANESE JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS","volume":"18 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75611786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient and Public Involvement Online in National Whole-genome Sequencing Project in Japan","authors":"H. Nakada, Megumu Yokono, A. Nagai","doi":"10.3999/jscpt.53.5_169","DOIUrl":"https://doi.org/10.3999/jscpt.53.5_169","url":null,"abstract":"The Japanese government developed a national-level whole genome sequencing project in December 2020, which is expected to promote precision medical care for cancer and rare disease patients. Since this is a nationwide project, there is a need for implementing patient and public involvement (PPI). Considering the current COVID-19 pandemic, we conducted online PPI to formulate the contents of the project's informed consent form (ICF) for participation. This online PPI aimed at gaining insights from cancer patients and their family members regarding the ICF. A one-day seminar was conducted online in September 2021, which included three lectures related to the national project, followed by discussion among the attendees divided into two groups based on their age and types of cancer. We had eight attendees who were cancer patients and/or their family members. They discussed the ICF's contents based on the draft developed by the project's research team. Online PPI has its merits and drawbacks. It allows for easier participation and is beneficial for patients who are unable to physically attend either because of their medical condition or geographical location. For the researcher also, it becomes easier to recruit a diverse variety of people who wish to join the PPI activities. In contrast, at times, participants find it difficult to use online devices. Moreover, the attendees may not feel comfortable with the online discussions owing to the lack of nonverbal expression and interactions when compared with personal interaction. For promoting PPIs in the future, we recommend considering the following three crucial aspects:practicing online PPI in a variety of situations, constructing a framework that enables PPI quickly, and promoting diversity in the attendees participating in such PPI activities. Copyright:©2022 the Japanese Society of Clinical Pharmacology and Therapeutics (JSCPT)","PeriodicalId":14602,"journal":{"name":"JAPANESE JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49313907","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Report of the 6th Annual Meeting of the Chugoku & Shikoku Region of the JSCPT","authors":"Shinji Kosaka","doi":"10.3999/jscpt.53.5_189","DOIUrl":"https://doi.org/10.3999/jscpt.53.5_189","url":null,"abstract":"","PeriodicalId":14602,"journal":{"name":"JAPANESE JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43991326","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Report of the 5th Annual Meeting of the Hokkaido & Tohoku Region of the JSCPT","authors":"Yoshikazu Tasaki","doi":"10.3999/jscpt.53.5_193","DOIUrl":"https://doi.org/10.3999/jscpt.53.5_193","url":null,"abstract":"","PeriodicalId":14602,"journal":{"name":"JAPANESE JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44633889","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Current and Issues Status of Ethics Review of Multi-center Research Projects: From the Viewpoint of the Secretariat of the Central Ethics Review Committee","authors":"Ryota Kitao, Takuya Watanabe, Shinji Kosugi","doi":"10.3999/jscpt.53.5_177","DOIUrl":"https://doi.org/10.3999/jscpt.53.5_177","url":null,"abstract":"","PeriodicalId":14602,"journal":{"name":"JAPANESE JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43374351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}